Clinical Application of AMH Measurement in Assisted Reproduction
- PMID: 33362720
- PMCID: PMC7757755
- DOI: 10.3389/fendo.2020.606744
Clinical Application of AMH Measurement in Assisted Reproduction
Abstract
Anti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction models it has limited ability to predict live birth and should not be used to refuse treatment, but rather to inform counselling and shared decision making. The use of absolute clinical thresholds to stratify patient phenotypes, assess discordance and individualize treatment protocols in non-validated algorithms combined with the lack of standardization of assays may result in inappropriate classification and sub-optimal clinical decision making. We propose that holistic baseline phenotyping, incorporating antral follicle count and other patient characteristics is critical. Treatment decisions driven by validated algorithms that use ovarian reserve biomarkers as continuous measures, reducing the risk of misclassification, are likely to improve overall outcomes for our patients.
Keywords: anti-Müllerian hormone; assisted reproduction; gonadotropin dosing; in vitro fertilization; intrauterine insemination; ovarian response.
Copyright © 2020 Li and Nelson.
Conflict of interest statement
SN reports personal fees from Access Fertility, personal fees and non-financial support from Ferring, personal fees and non-financial support from Merck, personal fees from Coopers Genomics, personal fees and non-financial support from Ferring Pharmaceuticals, personal fees from The Fertility Partnership, grants, personal fees and non-financial support from Roche Diagnostics, personal fees from Modern Fertility, other from Delivery I, outside the submitted work. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.Hum Reprod. 2017 Apr 1;32(4):811-819. doi: 10.1093/humrep/dex012. Hum Reprod. 2017. PMID: 28175316 Clinical Trial.
-
Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.Reprod Biomed Online. 2013 Oct;27(4):390-9. doi: 10.1016/j.rbmo.2013.07.008. Epub 2013 Jul 23. Reprod Biomed Online. 2013. PMID: 23953069 Clinical Trial.
-
Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.Fertil Steril. 2009 Nov;92(5):1586-93. doi: 10.1016/j.fertnstert.2008.08.127. Epub 2008 Oct 18. Fertil Steril. 2009. PMID: 18930213 Clinical Trial.
-
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice.Hum Reprod Update. 2014 Jan-Feb;20(1):124-40. doi: 10.1093/humupd/dmt037. Epub 2013 Sep 29. Hum Reprod Update. 2014. PMID: 24077980 Review.
-
Individualization of controlled ovarian stimulation in vitro fertilization using ovarian reserve markers.Minerva Ginecol. 2017 Jun;69(3):250-258. doi: 10.23736/S0026-4784.17.04044-8. Epub 2017 Mar 7. Minerva Ginecol. 2017. PMID: 28271699 Review.
Cited by
-
High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.Front Endocrinol (Lausanne). 2021 May 26;12:673284. doi: 10.3389/fendo.2021.673284. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34122349 Free PMC article.
-
Anti-Müllerian hormone: biology and role in endocrinology and cancers.Front Endocrinol (Lausanne). 2024 Sep 16;15:1468364. doi: 10.3389/fendo.2024.1468364. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39351532 Free PMC article. Review.
-
The Exploration of Poor Ovarian Response-Related Risk Factors: A Potential Role of Growth Differentiation Factor 8 in Predicting Ovarian Response in IVF-ET Patient.Front Endocrinol (Lausanne). 2021 Sep 24;12:708089. doi: 10.3389/fendo.2021.708089. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34630324 Free PMC article.
-
Personalized prediction of the secondary oocytes number after ovarian stimulation: A machine learning model based on clinical and genetic data.PLoS Comput Biol. 2023 Apr 27;19(4):e1011020. doi: 10.1371/journal.pcbi.1011020. eCollection 2023 Apr. PLoS Comput Biol. 2023. PMID: 37104276 Free PMC article.
-
Age-related Curves of AMH Using the Gen II, the picoAMH, and the Elecsys Assays in Women With Polycystic Ovary Syndrome.J Clin Endocrinol Metab. 2024 Sep 16;109(10):2561-2570. doi: 10.1210/clinem/dgae153. J Clin Endocrinol Metab. 2024. PMID: 38486510 Free PMC article.
References
-
- Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I. Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol (2007) 23(8):486–93. 10.1080/09513590701532815 - DOI - PubMed
-
- Li HWR, Lee VCY, Lau EYL, Yeung WSB, Ho PC, Ng EHY. Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. PLoS One (2013) 8(4):e61095. 10.1371/journal.pone.0061095 - DOI - PMC - PubMed
-
- Anderson RA, Anckaert E, Bosch E, Dewailly D, Dunlop CE, Fehr D, et al. Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril (2015) 103(4):1074–80.e4. 10.1016/j.fertnstert.2015.01.004 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources